Flurbiprofen — How Dangerous It Is, Side Effects and Contraindications

EFFECTIVE | TOXIC

Under What Names Flurbiprofen Is Found

The international nonproprietary name is flurbiprofen; the Latin spelling is flurbiprofen, with the variants flurbiprofène and flurbiprofeno also encountered. For systemic use, flurbiprofen is available in tablets, usually containing 50 or 100 mg. For the treatment of sore throat, lozenges and an oromucosal spray containing 8.75 mg of flurbiprofen per dose are used. In ophthalmology, the sodium salt — flurbiprofen sodium — is used, primarily as 0.03% eye drops. The main brand names in different countries include Ansaid, FlurbiPro, Froben, Antadys, Majezik, Strefen, Strepfen, Strepsils Intensive, Strepsils Max Pro, Benactiv, Ocufen, and Ocuflur. Strefen, Strepfen, and some products in the Strepsils range may be perceived as ordinary throat lozenges, although their active ingredient is the NSAID flurbiprofen. No widely used fixed combinations of flurbiprofen with other analgesics have been registered; however, inadvertent duplication can occur when flurbiprofen spray, lozenges, tablets, or eye drops are used simultaneously, as well as when flurbiprofen is combined with other NSAIDs. Ophthalmic preparations contain flurbiprofen sodium, but pharmacologically they contain the same active drug.

Why Flurbiprofen Is Considered Harmless and Where the Real Risk Begins

Flurbiprofen is often perceived as a topical treatment for sore throat because it is sold as a spray or familiar lozenges. However, the drug is rapidly absorbed through the mucous membrane and can be detected in the blood within minutes. It is not an antiseptic candy but a cyclooxygenase inhibitor with systemic effects capable of damaging the gastric and intestinal mucosa, impairing renal blood flow, inhibiting platelet aggregation, provoking bronchospasm, and masking progression of an infection. Although the concentration of flurbiprofen after a lozenge is lower than after a 50 mg tablet, it is not zero, and repeated doses increase total exposure. It is particularly dangerous to use lozenges and spray while simultaneously taking ibuprofen, naproxen, ketoprofen, diclofenac, or aspirin: the names are different, but the toxicological burden is cumulative. Early manifestations — burning in the mouth, nausea, abdominal discomfort, headache, or dizziness — are nonspecific, so a patient may continue using the drug until bleeding, bronchospasm, edema, or reduced urine output develops.

Side Effects After the First Dose and a Short Course

The most common reactions to lozenges and spray are irritation, burning, tingling, or numbness of the oral and pharyngeal mucosa, oral pain, mucosal ulceration, altered taste, nausea, diarrhea, headache, dizziness, and paresthesia. Some patients interpret pharyngeal numbness as a pronounced therapeutic effect, although it may impair swallowing control and mask ongoing inflammation.

Clinically significant reactions include epigastric pain, dyspepsia, vomiting, exacerbation of ulcerative colitis or Crohn’s disease, increased blood pressure, fluid retention, peripheral edema, deterioration of kidney function, anemia, thrombocytopenia, and drug-induced hepatitis. Flurbiprofen inhibits the synthesis of protective prostaglandins and platelet aggregation, which means that gastrointestinal bleeding, ulceration, or perforation may occur without prominent warning symptoms.

Life-threatening reactions are possible even after the first doses: anaphylaxis, swelling of the face or larynx, severe bronchospasm, especially in aspirin-induced asthma, gastrointestinal bleeding, acute kidney failure, and severe bullous skin reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis. Rash, blisters, mucosal erosions, difficulty breathing, black stools, or vomiting blood require immediate discontinuation of the drug.

Consequences of Long-Term and Repeated Use

Flurbiprofen lozenges and spray are intended for use for no more than three days. Continuing treatment for weeks turns a small single dose into repeated systemic exposure to an NSAID. The likelihood of erosive and ulcerative damage to the stomach and intestines, occult blood loss, iron-deficiency anemia, increased blood pressure, edema, and decompensated heart failure gradually increases.

Suppression of renal prostaglandins reduces blood supply to the kidneys, particularly during dehydration, use of diuretics, heart failure, or pre-existing kidney disease. This may result in a reduced glomerular filtration rate, sodium and potassium retention, hyperkalemia, interstitial nephritis, nephrotic syndrome, or acute kidney failure. Early functional impairment is often reversible after discontinuation, but severe or repeated injury can leave a persistent reduction in kidney function.

High systemic doses and prolonged use increase the risk of myocardial infarction and ischemic stroke. Increased liver enzyme activity, hepatitis, and, extremely rarely, liver failure are possible. In women, cyclooxygenase inhibition may temporarily interfere with ovulation and reduce fertility; this effect is usually reversible after treatment is discontinued.

Flurbiprofen does not cause classic drug dependence or a specific withdrawal syndrome. However, repeated use of an analgesic may lead to medication-overuse headache, while pain relief in the throat can mask bacterial tonsillitis, pneumonia, or another progressive infectious disease. Absence of pain after a lozenge does not mean that the cause of the illness has been eliminated.

Contraindications and High-Risk Groups

Flurbiprofen is contraindicated in people with an allergy to flurbiprofen, aspirin, or other NSAIDs, as well as in those who have previously developed bronchospasm, an asthma attack, urticaria, rhinitis, or angioedema after taking these drugs. Repeated exposure may cause a more severe reaction, including anaphylaxis.

The drug must not be used in active or recurrent peptic ulcer disease, previous gastrointestinal bleeding, or perforation, particularly if the complication was associated with an NSAID. Flurbiprofen can cause recurrent bleeding without preceding pain. Exacerbation of the disease is possible in ulcerative colitis and Crohn’s disease.

Severe heart, kidney, or liver failure are contraindications. In heart failure, the drug increases sodium and fluid retention; in renal dysfunction, it can sharply impair filtration; in severe liver disease, the free fraction of the drug and the risk of bleeding increase.

Older patients are more likely to experience ulcer bleeding and perforation without typical pain, and the consequences of blood loss and kidney failure are more severe in this group. High risk is also characteristic of patients with arterial hypertension, ischemic heart disease, cerebrovascular disease, dehydration, diabetes mellitus, and concomitant use of diuretics.

Lozenges and spray are not intended for children under 12 years of age. In the third trimester of pregnancy, flurbiprofen is contraindicated because of the risk of premature closure of the ductus arteriosus, fetal pulmonary hypertension, renal failure and oligohydramnios, as well as prolonged bleeding and delayed labor. Beginning at approximately the 20th week of pregnancy, systemic NSAIDs can impair fetal kidney function, so self-medication is unacceptable. Oromucosal formulations are not recommended during breastfeeding.

Dangerous Drug and Everyday-Life Combinations

Contraindicated or highly undesirable: simultaneous use of flurbiprofen with other NSAIDs, including ibuprofen, naproxen, ketoprofen, diclofenac, ketorolac, nimesulide, and selective COX-2 inhibitors. Such a combination provides almost no additional pain relief but increases the likelihood of ulceration, bleeding, kidney failure, and elevated blood pressure. Combination with aspirin also increases the risk of complications; low-dose aspirin prescribed by a cardiologist should not be discontinued independently, but adding flurbiprofen requires a risk assessment.

High risk of bleeding: warfarin, apixaban, rivaroxaban, dabigatran, heparins, clopidogrel, and other antiplatelet agents. Flurbiprofen damages the gastrointestinal mucosa and inhibits platelet function, while anticoagulants simultaneously inhibit blood coagulation. Glucocorticoids and selective serotonin reuptake inhibitors additionally increase the risk of ulceration and bleeding.

Risk of kidney failure: ACE inhibitors, angiotensin II receptor blockers, and diuretics. The combination of an NSAID with a diuretic and an ACE inhibitor or an angiotensin receptor blocker is known as the “triple whammy” to the kidneys: blood flow into the glomerulus decreases, compensation of intrarenal pressure is disrupted, and filtration falls sharply. Cyclosporine and tacrolimus further increase nephrotoxicity.

Requires laboratory monitoring: lithium — flurbiprofen reduces its renal clearance and increases its concentration, creating a risk of tremor, ataxia, confusion, and seizures. Methotrexate, especially when taken within a day before or after an NSAID, may accumulate and cause myelosuppression, mucositis, hepatotoxicity, and nephrotoxicity. Increased concentrations of digoxin and phenytoin are possible, as is hyperkalemia with potassium-sparing diuretics.

Flurbiprofen may weaken the effects of antihypertensive drugs and diuretics. NSAIDs are not recommended for 8–12 days after mifepristone because they may reduce its effect. Quinolone antibiotics may theoretically increase susceptibility to seizures when combined with NSAIDs.

Alcohol is highly undesirable: it increases damage to the gastric mucosa and raises the likelihood of gastrointestinal bleeding. Smoking is also associated with a higher risk of ulcer-related complications. No specific clinically significant interaction with caffeine has been established; however, caffeine does not protect the stomach or compensate for NSAID toxicity.

Herbal preparations and dietary supplements with antiplatelet effects — concentrated extracts of ginkgo, garlic, ginger, turmeric, sweet clover, willow, meadowsweet, and danshen — may further increase the tendency to bleed. Willow and meadowsweet contain salicylate derivatives and should not automatically be combined with flurbiprofen as a form of “natural enhancement.”

Typical Patient Mistakes

The main mistake is treating flurbiprofen as a topical lozenge without taking into account that it belongs to the NSAID class. A person sucks a throat lozenge, then takes ibuprofen for fever or diclofenac for back pain and does not realize that several cyclooxygenase inhibitors are being used at the same time.

The second mistake is shortening the intervals between doses. If the pain returns sooner, the patient uses another lozenge or sprays again, although recurrence of pain does not mean that the dose is insufficient: it may indicate ongoing inflammation, a bacterial infection, a peritonsillar process, or another cause that the drug does not treat.

Flurbiprofen lozenges and spray should not be used simultaneously unless the total dose has been calculated according to the instructions for the specific products. Do not exceed five doses of 8.75 mg within 24 hours or use oromucosal formulations for more than three days without reassessing the diagnosis. Increasing the number of lozenges intensifies not only local irritation but also systemic exposure.

It is dangerous to continue treatment if abdominal pain, black stools, vomiting blood, reduced urine output, edema, wheezing, rash, or mucosal lesions occur. Flurbiprofen should not be used to mask worsening throat pain, high fever, purulent coating, unilateral swelling, difficulty opening the mouth, or difficulty breathing.

Another common mistake is combining the drug with alcohol and taking it on an empty stomach. Food may reduce dyspepsia but does not eliminate the risk of ulceration, bleeding, renal toxicity, or cardiovascular toxicity. The over-the-counter status of lozenges does not make flurbiprofen a safe product for uncontrolled use.

Flurbiprofen Overdose and Poisoning

There is no single reliably established toxic dose of flurbiprofen for humans: the severity of poisoning depends on the dosage form, body weight, age, kidney and liver function, dehydration, and other medications taken at the same time. For lozenges, the recommended limit is five doses of 8.75 mg per day, with treatment lasting no more than three days. Exceeding this amount does not mean that severe poisoning is inevitable, but it requires assessment of the total dose and risk factors.

During the first hours, nausea, vomiting, epigastric pain, diarrhea, headache, dizziness, tinnitus, and drowsiness usually occur. These manifestations may appear minor, although severe overdose may later lead to gastrointestinal bleeding, disorientation, agitation or depressed consciousness, visual disturbances, and seizures.

Severe poisoning is accompanied by metabolic acidosis, prolonged prothrombin time and INR, acute kidney failure, liver injury, bronchospasm, and coma. Patients with asthma may experience a sharp exacerbation of respiratory failure. Dehydration, older age, chronic kidney disease, heart failure, cirrhosis, anticoagulants, and the use of several NSAIDs reduce the dose at which severe complications may occur.

A concealed overdose may develop when flurbiprofen lozenges and spray are combined, when systemic tablets are used in parallel, or when ibuprofen, ketoprofen, naproxen, diclofenac, or aspirin is added. Strictly speaking, this is not an overdose of a single substance, but the cumulative suppression of prostaglandins produces a similar toxicological picture.

There is no specific antidote for flurbiprofen. Treatment is supportive: monitoring of breathing, consciousness, blood pressure, ECG, electrolytes, acid-base status, kidney and liver function, and blood coagulation. Activated charcoal is considered by medical professionals mainly within the first hour after a potentially toxic ingestion; vomiting should not be induced independently. Because flurbiprofen is highly bound to plasma proteins, dialysis is not considered an effective method of removing the drug. If the dose is exceeded, if a child ingests an unknown amount, or if drowsiness, blood in vomit or stool, seizures, shortness of breath, or reduced urine output develops, it is unsafe to wait for further symptoms — emergency toxicology care is required.

A Safe Integrative Alternative to Flurbiprofen

For acute inflammatory sore throat, pharyngitis, tonsillitis, rhinopharyngitis, and influenza-like syndrome, Anti-Inflammatory “5 Roots” Mixture — Five Root Compound may be considered as an integrative alternative. The formula contains roots of Harrisonia perforata, Capparis micracantha, Clerodendrum petasites, Ficus racemosa, and Tiliacora triandra. The composition combines anti-inflammatory, analgesic, antipyretic, antioxidant, and immunomodulatory effects. Its pharmacological rationale includes reducing the production of nitric oxide and pro-inflammatory cytokines, suppressing COX-2-dependent prostaglandin synthesis, and reducing oxidative tissue damage.

Flurbiprofen directly inhibits cyclooxygenase and reduces pain, difficulty swallowing, and the sensation of throat swelling more rapidly. “Five Roots” acts more broadly, but the effect may develop less rapidly and depends on the severity of inflammation, the formulation used, and individual sensitivity. In mild to moderate uncomplicated pharyngitis, rhinopharyngitis, or inflammatory pain, the herbal composition may be used as a full substitute for flurbiprofen. With high fever, purulent tonsillitis, pronounced unilateral pain, difficulty breathing, or suspected peritonsillar abscess, anti-inflammatory treatment alone is insufficient: the cause of the illness must be diagnosed.

The advantage of Five Root Compound is the absence of the direct suppression of gastric mucosal protective prostaglandins and renal blood flow that is characteristic of NSAIDs. The published evidence for the ingredients of the formula is predominantly experimental, phytochemical, and preclinical; there are no large direct comparative studies with flurbiprofen. This limits the precision of quantitative comparisons of efficacy but does not negate the established pharmacological rationale of the composition. Based on the available data, the main limitations of the mixture are individual hypersensitivity, dyspepsia if the dose is exceeded, and insufficient data for pregnant women, breastfeeding women, and children under 12 years of age.

How Effective Flurbiprofen Really Is

Flurbiprofen is effective as a symptomatic anti-inflammatory analgesic. Lozenges and spray at a dose of 8.75 mg reduce the intensity of sore throat, difficulty swallowing, and the sensation of swelling. Relief may become noticeable approximately 15–30 minutes after administration and may persist for several hours. Clinical studies show that low-dose topical flurbiprofen is superior to placebo lozenges, although the absolute effect varies among studies and usually remains moderate.

The drug does not destroy viruses or bacteria, does not treat an abscess, and does not eliminate gastroesophageal reflux, allergy, or another cause of sore throat. It temporarily suppresses prostaglandin synthesis and reduces inflammatory symptoms. Therefore, disappearance of pain after a lozenge does not confirm recovery and does not rule out progression of an infection.

Systemic flurbiprofen can reduce pain, stiffness, and inflammation in osteoarthritis and rheumatoid arthritis, but it likewise does not alter the cause or natural course of the disease. Its use is justified when a predictable anti-inflammatory effect is required; however, systemic doses are associated with the typical risks of NSAIDs — ulcer bleeding, cardiovascular complications, fluid retention, and impaired kidney function.

A common medical error is prescribing flurbiprofen for sore throat without assessing its cause and allowing prolonged treatment if symptoms persist. Another error is failing to account for concomitant use of aspirin, ibuprofen, diclofenac, anticoagulants, diuretics, or lithium preparations. Flurbiprofen is effective against the symptom, but it does not acquire additional therapeutic properties simply because the patient likes the numbness of the mucosa.

Safety Monitoring During Treatment

When lozenges or spray are used for no more than three days, special laboratory monitoring is generally not required in a person without risk factors. It is necessary to watch for abdominal pain, heartburn, nausea, black stools, blood in vomit, reduced urine output, edema, increased blood pressure, wheezing, skin rash, and mucosal lesions.

With systemic use or repeated courses, blood pressure, complete blood count, hemoglobin, hematocrit, creatinine, estimated glomerular filtration rate, urea, potassium, ALT, and AST should be monitored. Tests are performed before a prolonged course begins, then approximately 1–2 weeks later in patients at increased risk, and subsequently at intervals depending on the dose, duration of treatment, and concomitant diseases. Long-term NSAID use requires monitoring of the complete blood count and biochemical parameters even in the absence of complaints because bleeding, anemia, and kidney dysfunction may remain clinically silent for a long time.

Flurbiprofen must be discontinued immediately in the event of gastrointestinal bleeding, a pronounced decrease in urine output, rapidly increasing edema, jaundice, dark urine, persistently elevated liver enzymes, bronchospasm, swelling of the face or larynx, generalized rash, blisters, or mucosal erosions. Chest pain, sudden shortness of breath, weakness on one side of the body, impaired speech, or altered consciousness may indicate myocardial infarction or stroke and require emergency care. Waiting in such situations is dangerous because blood loss, anaphylaxis, acute kidney failure, and severe skin reactions can rapidly become irreversible.

How to Stop Taking Flurbiprofen Correctly

Flurbiprofen does not cause physical dependence and does not require gradual dose reduction. Lozenges, spray, and systemic tablets can be stopped immediately. No specific withdrawal syndrome occurs.

After discontinuation, pain, inflammation, or stiffness may return because the drug suppresses symptoms but does not eliminate their cause. The return of pain is not a sign of drug dependence and does not mean that flurbiprofen must immediately be taken again. If a sore throat persists for more than three days, the fever worsens, or purulent coating, unilateral swelling, or difficulty swallowing develops, the diagnosis should be reassessed.

During long-term treatment of arthritis, abrupt discontinuation of flurbiprofen does not cause a pharmacological rebound effect, but it may result in the return of pain and restricted mobility. Therefore, disease-modifying therapy, physical activity, and the possibility of switching to an agent with a lower toxicological burden should be assessed at the same time. Discontinuation of flurbiprofen should be distinguished from discontinuation of glucocorticoids: after prolonged use, the latter require gradual dose reduction.

A Rational Approach to Flurbiprofen Use

Flurbiprofen is justified when rapid and predictable reduction of inflammatory pain is required and contraindications and dangerous interactions have been excluded. For short-term acute pain, it may provide a faster effect than most herbal formulations.

For mild or moderate throat inflammation, especially if the patient has a history of peptic ulcer disease, NSAID intolerance, chronic kidney disease, or is taking anticoagulants, it is reasonable to consider Anti-Inflammatory “5 Roots” Mixture as an alternative with a different pharmacological and toxicological burden. This does not mean that a herbal product is automatically safe for every patient: allergies, pregnancy, age, and the quality of the raw materials must be taken into account.

Combined use of flurbiprofen and “Five Roots” is usually unnecessary for uncomplicated pain. The combination increases the complexity of therapy and makes tolerability more difficult to assess without guaranteeing a proportional increase in effect. In severe, rapidly progressing, or complicated disease, treatment choice should be determined by the diagnosis rather than by an attempt to replace one analgesic with another at any cost.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or schedule an appointment using this link: https://asiabiopharm.com/konsultaciii/